中牧股份(600195.SH)上半年淨利1.62億元同比降15.65%
格隆匯8月21日丨中牧股份(600195.SH)披露2019年半年度報告，報告期內公司實現營業收入18.35億元，同比下降3.21%；歸屬於上市公司股東的淨利潤1.62億元，同比下降15.65%；經營活動現金淨流出2.37億元，而上年同期為淨流出1.48億元；基本每股收益0.2697元，加權平均淨資產收益率3.98%。
報告期末，公司總資產57.55億元，較上年度末減少15.89%；歸屬於上市公司股東的淨資產41.60億元，較上年度末增加4.11%。
生物製品：上半年，受非洲豬瘟疫情影響，生豬存欄量鋭減，養殖户補欄意願不積極，並且養殖户通過加強消毒、嚴格管理等生物安全措施，一定程度上導致了部分品類的畜苗用量減少，畜苗產品市場的整體需求縮減，公司產品的銷量也隨之下降，不及預期。
在禽用疫苗產品方面，公司及時把握住養禽業景氣度上升帶來的業務機會，堅持以高附加值產品為抓手加大市場化禽用疫苗產品銷售力度，與事業合作伙伴深入合作，加強渠道建設，大型集團客户開發效果逐步顯現，實現高附加值產品收入大幅增長；同時，政府採購禽流感疫苗因毒株更換推動產品價格提升。上半年公司禽用疫苗收入與去年同期相比增幅明顯，毛利額取得較好增長，出口實現的收入進一步提升。
獸用化藥：依據行業監管政策，喹乙醇產品已於2018年5月1日起停止生產，2019年5月1日起停止使用。受此影響，今年上半年公司獸用化藥業務板塊收入、毛利額減少。同時，非洲豬瘟疫情對生豬養殖行業衝擊較大，導致獸用化藥市場需求低迷，豬用化藥產品收入下降明顯。
針對藥政藥事法規變化帶來的影響，公司加大新產品開發，加快新舊動能轉換，拓展外向型經濟。近期，經美國FDA審計官對勝利生物的質量系統、物料系統、包裝和貼籤系統、生產系統、廠房設施設備和實驗室控制系統進行現場審查，勝利生物以零缺陷的成績通過了美國FDA現場審計，這將為化藥產品擴大出口創造有利條件。
飼料及飼料添加劑：公司繼續保持蛋雞飼料產品市場競爭優勢，並順勢加快開發和推廣其他家禽飼料產品，通過技術引領進一步拓展家禽預混料市場；積極開發反芻料領域特色產品；加強營銷力量建設，實施價值營銷、協同銷售，細化經銷商佈局，抓好大客户直銷。上半年，預混料銷量和收入增幅明顯。
貿易：公司在嚴控風險前提下，以利潤為導向，積極應對市場變化，及時調整銷售節奏。上半年加大庫存銷售，銷量同比增幅較大，通過穩定上游供應渠道、把握行情波動機會，利潤整體完成情況較好。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
